免疫性血小板减少症
流行病学
医学
人口
免疫学
儿科
内科学
抗体
环境卫生
作者
Ji Yun Lee,Faqiang Li,Heeyoung Lee,Beodeul Kang,Ji‐Won Kim,Se Hyun Kim,Jeong‐Ok Lee,Jin Won Kim,Yu Jung Kim,Keun‐Wook Lee,Jee Hyun Kim,Hyoung Soo Choi,Jong Seok Lee,Soo‐Mee Bang
标识
DOI:10.1016/j.thromres.2017.05.010
摘要
Abstract
Introduction
The epidemiology of immune thrombocytopenia (ITP) is not well characterized in an Asian population. Materials and methods
From July 2010 to June 2014, ITP patients were identified using the Korean Health Insurance Review and Assessment Service database. Results
The overall incidence rate of ITP was 5.3 per 100,000 person-years (95% CI: 5.1–5.5). The overall incidence rate ratios of children under 15years old to adults and females to males were 3.8 (95% CI: 3.7–3.9) and 1.3 (95% CI: 1.2–1.4), respectively. Of the total 10,814 patients, 3388 patients (31%) needed treatment for ITP; of these, 54% continued treatment for more than three months. First-line therapy consisted of corticosteroids (CS) in 42%, immunoglobulin (IVIg) in 35%, CS with IVIg in 19%, and other immunosuppressive agents (ISA) in 4%. Among treated patients, 75% of adults and 33% of children continued treatment for more than three months. After three months, the most frequently used drug was CS alone in 63% of patients. Only 104 patients underwent splenectomy; of these, 51% received salvage treatment after a median of one month after surgery (range: 0–27). The proportion of patients who received platelet transfusions of 12units or more per month for at least two consecutive months was significantly higher among patients treated for more than three months compared with patients who completed treatment within three months. Conclusions
This population-based study is the first to describe the incidence of ITP and its treatment reality for patients in Korea.
科研通智能强力驱动
Strongly Powered by AbleSci AI